• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NASA scientists take on muscular atrophy with drug-loaded implant

January 29, 2018 By Sarah Faulkner

NASA Scientists aboard the International Space Station plan to study if a drug-eluting implant can prevent, slow or even turn back the muscular breakdown observed in astronauts when they fly for an extended period of time.

The investigation is designed to test the efficacy of a drug and a nano-channel drug-delivery system in a space-bound mouse model.

The drug-delivery device, which is about as big as a grain of rice, includes channels that are just two to three nanometers in size. The drug is delivered using simple diffusion, instead of through a pump, according to the researchers.

Once all of the drug has been delivered, the implant can be refilled without being removed.

“The unique aspect of the mission is the nano-channel delivery system is implanted under the skin and provides constant drug delivery in the body, which prevents the need for injections or taking pills,” Yasaman Shirazi, the project’s mission scientist, said in prepared remarks, “and if you want to look at it long-term, it could be a customized device for long-term curing of a disease.”

“We realized if we use channels comparable in size to the drug molecule of interest, we can achieve a very steady, controlled delivery of drug outside of an implanted reservoir for a period of time ranging from up to months and years without any sort of pumping mechanism onboard our implants,” Alessandro Grattoni, the project’s primary investigator, added.

Novartis Institutes for Biomedical Research is participating in the investigation, as well as BioServe, Houston Methodist Research Institute, the Center for the Advancement of Science in Space and NASA’s Ames Research Center.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: Novartis

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS